MSD
MK 3475/Pembrolizumab +MK5890/MK4830/Lenvatinib + Etoposide/Platinum
Biodrugs/ Drugs
Cancer
Platform trial: To Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination w/Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants w/Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)
2Phase II in Spain,
1Phase I